Becton, Dickinson plans to reduce debt and repurchase $1B in shares. Read why BDX stock is a solid Buy, enhancing financial ...

Q4 2024 Earnings Call Transcript November 7, 2024 Operator: Hello and welcome to BD’s Fourth Quarter and Full Year Fiscal ...

On Thursday, Becton, Dickinson and Company (NYSE:BDX) reported fourth-quarter sales of $5.44 billion, up 6.9% year over year ...

BD (NYSE:BDX) shares ticked up before hours today on fourth-quarter results that came in ahead of the consensus forecast.

Becton Dickinson (BDX) Company Description: Founded in 1897, Becton, Dickinson & Co. is a New Jersey-based medical technology company. The company develops, manufactures and sells medical supplies, ...

Becton Dickinson and Co Michael Garrison; Executive Vice President, President - Medical Segment; Becton Dickinson and Co Hello, and welcome to BD's fourth-quarter and full year fiscal 2024 ...

Becton, Dickinson and Co. (BD) is a prominent global medical technology company that specializes in advancing healthcare through innovative solutions in diagnostics, medical discovery, and care ...

Morgan Stanley analyst Patrick Wood maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of ...

Shares are modestly undervalued. BD Medical was a top-performing segment in the quarter, with the currency-neutral growth of 12%. While pharma systems business still saw some lingering effects of ...

BD Medical segment sales increased to $2.84 billion, up 11.1%. Medication Management Solutions led organic revenue growth of 8.6%. BD Life Sciences sales were almost flat to $1.34 billion ...